JP2008500025A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500025A5
JP2008500025A5 JP2006553229A JP2006553229A JP2008500025A5 JP 2008500025 A5 JP2008500025 A5 JP 2008500025A5 JP 2006553229 A JP2006553229 A JP 2006553229A JP 2006553229 A JP2006553229 A JP 2006553229A JP 2008500025 A5 JP2008500025 A5 JP 2008500025A5
Authority
JP
Japan
Prior art keywords
antibody
acid sequence
seq
amino acid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006553229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500025A (ja
JP4805848B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/004240 external-priority patent/WO2005080431A2/en
Publication of JP2008500025A publication Critical patent/JP2008500025A/ja
Publication of JP2008500025A5 publication Critical patent/JP2008500025A5/ja
Application granted granted Critical
Publication of JP4805848B2 publication Critical patent/JP4805848B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006553229A 2004-02-12 2005-02-11 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体 Expired - Lifetime JP4805848B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54436404P 2004-02-12 2004-02-12
US60/544,364 2004-02-12
PCT/US2005/004240 WO2005080431A2 (en) 2004-02-12 2005-02-11 Monoclonal antibodies that specifically bind to folate receptor alpha

Publications (3)

Publication Number Publication Date
JP2008500025A JP2008500025A (ja) 2008-01-10
JP2008500025A5 true JP2008500025A5 (enExample) 2011-08-18
JP4805848B2 JP4805848B2 (ja) 2011-11-02

Family

ID=34886025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006553229A Expired - Lifetime JP4805848B2 (ja) 2004-02-12 2005-02-11 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体

Country Status (6)

Country Link
US (4) US20050232919A1 (enExample)
EP (3) EP2316857A1 (enExample)
JP (1) JP4805848B2 (enExample)
AU (1) AU2005214331B2 (enExample)
CA (1) CA2556027C (enExample)
WO (1) WO2005080431A2 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004249673A1 (en) * 2003-05-23 2004-12-29 Morphotek, Inc. Anti alpha - folate - receptor - tetramer antibodies
US20050054048A1 (en) * 2003-07-29 2005-03-10 Luigi Grasso Antibodies and methods for generating genetically altered antibodies with enhanced effector function
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
JP2010520748A (ja) 2007-02-20 2010-06-17 アナプティスバイオ インコーポレイティッド 体細胞超変異系
AU2014203172B2 (en) * 2010-02-24 2016-03-10 Immunogen, Inc. Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
SG10201501342UA (en) * 2010-02-24 2015-04-29 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
CN102782131B (zh) 2010-03-02 2015-08-05 协和发酵麒麟株式会社 修饰抗体组合物
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012054654A2 (en) * 2010-10-20 2012-04-26 Morphotek, Inc. Anti-folate receptor alpha antibody glycoforms
SG189957A1 (en) 2010-11-05 2013-06-28 Morphotek Inc Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
AU2012207356A1 (en) * 2011-01-18 2013-08-01 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
US20140010756A1 (en) 2011-03-18 2014-01-09 Kagoshima University Composition for treatment and diagnosis of pancreatic cancer
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
SI2694106T1 (en) * 2011-04-01 2018-04-30 Immunogen, Inc. Methods for increasing the effectiveness of treatment with FOLR1 receptor cancer
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
SI2731972T1 (en) 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9629918B2 (en) 2012-02-29 2017-04-25 Purdue Research Foundation Folate receptor alpha binding ligands
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
MX362497B (es) 2012-05-15 2019-01-21 Eisai Inc Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
US9200073B2 (en) * 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
CN104884617B (zh) * 2012-12-07 2019-02-19 协和发酵麒麟株式会社 抗folr1抗体
US9089614B2 (en) 2012-12-21 2015-07-28 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
US9522196B2 (en) 2012-12-25 2016-12-20 Kagoshima University Antibody recognizing folate receptors α and β
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20140363451A1 (en) * 2013-05-14 2014-12-11 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
EP3011013A4 (en) 2013-06-20 2017-03-15 Morphotek, Inc. Methods for treatment of ovarian cancer
CA3222465A1 (en) 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
JPWO2015186823A1 (ja) * 2014-06-06 2017-04-20 協和発酵キリン株式会社 Folr1標的薬および葉酸代謝拮抗剤によるがん患者のための治療方法並びに医薬
JP2017528418A (ja) * 2014-06-20 2017-09-28 バイオアライアンス コマンディテール フェンノートシャップ 抗葉酸受容体アルファ(fra)抗体−薬物コンジュゲート及びその使用方法
LT3789402T (lt) 2014-11-20 2022-09-26 F. Hoffmann-La Roche Ag Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
RS60615B1 (sr) 2014-11-20 2020-08-31 Hoffmann La Roche Zajednički laki lanci i postupci upotrebe
CN107074955B (zh) 2014-11-20 2021-06-22 豪夫迈·罗氏有限公司 针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
EP3034130B1 (en) 2014-12-19 2019-12-04 Althia Health, S.L. Monoclonal antibody for the diagnosis, treatment and/or prevention of brain tumors and brain lesions
US20180125970A1 (en) * 2015-04-17 2018-05-10 Morphotek, Inc. Methods for treating lung cancer
CN116440279A (zh) 2015-09-17 2023-07-18 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
ES2880731T3 (es) 2016-01-08 2021-11-25 Altrubio Inc Anticuerpos anti-PSGL-1 tetravalentes y usos de los mismos
KR102456433B1 (ko) 2016-03-02 2022-10-19 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド (エイチケイ) リミテッド 多重特異性Fab融合タンパクおよびその使用
EP3496757A4 (en) 2016-08-12 2020-04-15 L.E.A.F Holdings Group LLC POLYGLUTAMATE ANTIFOLATES AND USES THEREOF.
US10822410B2 (en) 2016-11-23 2020-11-03 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
US12310966B2 (en) 2018-02-07 2025-05-27 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
EP3749317A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES
WO2019157145A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
CA3090506A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
US12076402B2 (en) 2018-02-07 2024-09-03 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
JP7491573B2 (ja) 2018-02-07 2024-05-28 エル.イー.エー.エフ. ホールディングス グループ エルエルシー アルファポリグルタミン酸化メトトレキセートおよびその使用
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
WO2019160734A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
CA3090753A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
CA3090989A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
WO2019160735A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
EP3752158A4 (en) 2018-02-14 2022-03-09 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED AMINOPTERINE AND USES THEREOF
CN115925952A (zh) * 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
KR102275930B1 (ko) * 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
IL305431B2 (en) 2018-06-01 2025-03-01 Eisai R&D Man Co Ltd Antibody-drug conjugates of splicing modulators and methods of use
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR20210102274A (ko) 2018-12-13 2021-08-19 에자이 알앤드디 매니지먼트 가부시키가이샤 헤르복시디엔 항체-약물 접합체 및 사용 방법
KR20220004687A (ko) 2019-04-29 2022-01-11 이뮤노젠 아이엔씨 이중파라토프 fr-알파 항체 및 면역접합체
CN111393528B (zh) * 2020-01-19 2023-01-31 中国药科大学 一种靶向叶酸受体α的单链抗体及其应用
CA3146977A1 (en) * 2020-04-15 2021-10-21 Zymeworks Inc. Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
CR20240375A (es) 2022-03-11 2025-01-06 Mablink Bioscience Conjugados anticuerpo-fármaco y sus usos
EP4342488A1 (en) 2022-09-26 2024-03-27 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor specific for folate receptor 1
CN118047871A (zh) * 2022-11-16 2024-05-17 迈威(上海)生物科技股份有限公司 一种靶向FRα的抗体或其抗原结合片段及其应用
CN116462768B (zh) * 2023-06-13 2023-09-22 浙江时迈药业有限公司 针对folr1的双特异性抗体及其用途
WO2025034965A1 (en) * 2023-08-09 2025-02-13 Board Of Regents, The University Of Texas System Targeted therapeutic delivery of lipid nanoparticles

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US4851332A (en) * 1985-04-01 1989-07-25 Sloan-Kettering Institute For Cancer Research Choriocarcinoma monoclonal antibodies and antibody panels
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5006470A (en) 1987-04-16 1991-04-09 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cell surface antigens of melanoma
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0554356B1 (en) 1990-10-12 1998-09-16 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce A monoclonal antibody
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5646253A (en) 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
DE4335025A1 (de) * 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
US6191268B1 (en) * 1993-12-17 2001-02-20 Dana-Farber Cancer Institute Compositions and methods relating to DNA mismatch repair genes
AU697269B2 (en) * 1994-01-27 1998-10-01 Human Genome Sciences, Inc. Human DNA mismatch repair proteins
DE19513676A1 (de) * 1995-04-11 1996-10-17 Behringwerke Ag Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli
DE19541844C1 (de) * 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
CA2241604C (en) * 1996-01-05 2010-03-30 Ira Pastan Mesothelium antigen and methods and kits for targeting it
ES2279539T3 (es) * 1996-05-04 2007-08-16 Astrazeneca Ab Anticuerpo monoclonal anti-cea, conjugados que comprenden dicho anticuerpo, y su uso terapeutico en un sistema adept.
US6809184B1 (en) * 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
US6146894A (en) * 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
US6365410B1 (en) * 1999-05-19 2002-04-02 Genencor International, Inc. Directed evolution of microorganisms
CA2374398C (en) 1999-05-27 2011-03-15 Ira Pastan Immunoconjugates having high binding affinity
ATE321870T1 (de) * 2000-06-05 2006-04-15 Corixa Corp Leader-anteile zur erhöhung der sekretion von rekombinanten proteine aus einer wirtzelle
US6808894B1 (en) 2000-11-07 2004-10-26 Morphotek, Inc. Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics
DE60041665D1 (de) * 2000-11-07 2009-04-09 Morphotek Inc Ten antikörperproduzierenden zelllinien mit verbesserten antikörpereigenschaften
CA2434926C (en) 2001-01-15 2014-04-01 Morphotek, Inc. Chemical inhibitors of mismatch repair
US7110683B2 (en) * 2001-03-30 2006-09-19 Agere Systems Inc. Compensation of polarization mode dispersion in single mode fiber for maximum-likelihood sequence estimation
NZ529808A (en) 2001-05-02 2007-02-23 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
BR0210905A (pt) * 2001-05-18 2004-06-08 Boehringer Ingelheim Int Anticorpos especìficos para cd44v6
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
GB2403222A (en) 2002-04-01 2004-12-29 Utah Ventures Ii L P Tissue-specific endothelial membrane proteins
GB0214013D0 (en) 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
WO2004009782A2 (en) * 2002-07-19 2004-01-29 Morphotek, Inc. Methods for generating enhanced antibody-producing cell lines with improved growth characteristics
AU2004249673A1 (en) * 2003-05-23 2004-12-29 Morphotek, Inc. Anti alpha - folate - receptor - tetramer antibodies
US20050054048A1 (en) 2003-07-29 2005-03-10 Luigi Grasso Antibodies and methods for generating genetically altered antibodies with enhanced effector function
CA2534659A1 (en) 2003-08-05 2005-02-17 Morphotek, Inc. A variant cell surface molecule associated with cancer
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
WO2006042158A2 (en) 2004-10-05 2006-04-20 Wyeth Methods and compositions for improving recombinant protein production
ES2429340T3 (es) * 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
WO2006105141A1 (en) 2005-03-30 2006-10-05 Purdue Research Foundation Method for cancer prognosis using cellular folate vitamin receptor quantification
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP1940473A2 (en) 2005-09-23 2008-07-09 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US20080032943A1 (en) 2005-11-04 2008-02-07 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
EP1900752A1 (en) 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
JP2010509570A (ja) 2006-11-03 2010-03-25 パーデュー・リサーチ・ファウンデーション エクスビボフローサイトメトリーの方法および装置
EP3569251A1 (en) 2007-06-25 2019-11-20 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US20090087849A1 (en) 2007-09-06 2009-04-02 Tripath Imaging, Inc. Nucleic acid-based methods and compositions for the detection of ovarian cancer
GB0725077D0 (en) 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
WO2009132081A2 (en) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Monoclonal antibody-based targeting of folate receptors

Similar Documents

Publication Publication Date Title
JP2008500025A5 (enExample)
US11013756B2 (en) Anti-IL-17 aptamer having improved retention in blood
JP2010519289A5 (enExample)
JP2009521206A5 (enExample)
JP2016511279A5 (enExample)
NZ610566A (en) Antibody purification
CY1122476T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι)
MX2009006277A (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
WO2007106811A3 (en) Method and composition for treatment of renal disease with antibodies and their equivalents
KR20170085593A (ko) 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도
NO20074911L (no) Behandling av benforstyrrelser
TN2009000194A1 (en) Novel antiproliferation antibodies
JP2009500431A5 (enExample)
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
US20150150994A1 (en) Liver targeted drug delivery systems using metal nanoparticles and preparing method thereof
Kwak et al. A Trojan-Horse strategy by in situ piggybacking onto endogenous albumin for tumor-specific neutralization of oncogenic MicroRNA
TW200831668A (en) Aptamer for midkine and use thereof
CN107405377A (zh) 外泌体的破坏方法、外泌体的破坏试剂盒及来自正常细胞的外泌体的分离方法
CN110354268A (zh) 一种核酸适配体及其环形二价核酸适配体-药物的偶联系统与应用
US11618901B2 (en) Anti-miRNA carrier conjugated with a peptide binding to a cancer cell surface protein and use thereof
AU2016242920B2 (en) Self assembling molecules for targeted drug delivery
JP5909611B2 (ja) 癌細胞選択的膜透過性ペプチドおよびその利用
JP2008539795A5 (enExample)
AU2004253475A1 (en) Leukocyte internalized peptide-drug conjugates
RU2010136988A (ru) Антигенсвязывающие полипептиды против дегенерации хряща